Phase II open label, multi-center clinical trial of modulation of intermediate endpoint biomarkers by 1α-hydroxyvitamin D2 in patients with clinically localized prostate cancer and high grade pin. (Q37127088)
Jump to navigation
Jump to search
scientific article published on 17 January 2013
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Phase II open label, multi-center clinical trial of modulation of intermediate endpoint biomarkers by 1α-hydroxyvitamin D2 in patients with clinically localized prostate cancer and high grade pin. |
scientific article published on 17 January 2013 |
Statements
1 reference
Phase II open label, multi-center clinical trial of modulation of intermediate endpoint biomarkers by 1α-hydroxyvitamin D2 in patients with clinically localized prostate cancer and high grade pin. (English)
1 reference
George Wilding
1 reference
Jason Gee
1 reference
Howard Bailey
1 reference
Kyungmann Kim
1 reference
Jill Kolesar
1 reference
Tom Havighurst
1 reference
Kendra D Tutsch
1 reference
William See
1 reference
Michael B Cohen
1 reference
Nick Street
1 reference
Leon Levan
1 reference
David Jarrard
1 reference
1 reference
1 reference
1 reference
1 reference
Identifiers
1 reference